Immuron Announces FDA Removed Clinical Hold on New Campylobacter ETEC Therapeutic Paves way for Clinical Trial Initiation
08 mai 2023 06h00 HE
|
Immuron Limited
Highlights: U.S. Food and Drug administration (FDA) remove clinical hold on New Campylobacter ETEC Therapeutic IND applicationUS Naval Medical Research Centre (NMRC) satisfactorily...
Immuron CEO, Steven Lydeamore to present at Coffee Microcaps
02 mai 2023 06h00 HE
|
Immuron Limited
MELBOURNE, Australia, May 02, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company that has developed two...
Immuron Q3 FY23 Business Update Presentation
19 avr. 2023 06h00 HE
|
Immuron Limited
MELBOURNE, Australia, April 19, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company that has developed two...
Q3 FY23 Business Update Webinar Notification
11 avr. 2023 06h00 HE
|
Immuron Limited
MELBOURNE, Australia, April 11, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company that has developed two...
Immuron Q3 Sales reach 150% of 1H Sales
06 avr. 2023 06h00 HE
|
Immuron Limited
Highlights: Australian Q3 FY23 sales of A$577 k (201% of 1H sales)North American Q3 FY23 Travelan® sales of A$298 k (100% of 1H sales)Global Q3 YTD FY23 sales of A$1.46 M represent an increase of...
Immuron CEO, Steven Lydeamore to host an investor webinar
15 févr. 2023 06h00 HE
|
Immuron Limited
MELBOURNE, Australia, Feb. 15, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDQ: IMRN), an Australian based and globally integrated biopharmaceutical company that has developed two...
Immuron US DoD Naval Medical Research Center responds to FDA Clinical Hold for New Campylobacter ETEC Therapeutic
25 janv. 2023 06h00 HE
|
Immuron Limited
MELBOURNE, Australia, Jan. 25, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company that has developed two...
US Department of Defense Uniformed Services University Clinical Evaluation of Travelan™ Achieves 150 Recruitment Milestone
18 janv. 2023 05h00 HE
|
Immuron Limited
Highlights: First participants enrolled in USU Travelan Clinical Trial Field Study157 participants successfully randomized into the Clinical StudyPlans in place to enrol in 1302 healthy volunteers in...
Immuron Receives European Patent on Drug Composition to Treat Clostridioides difficile Associated Disease
17 janv. 2023 07h10 HE
|
Immuron Limited
MELBOURNE, Australia, Jan. 17, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company that has developed two...
Immuron Receives FDA Approval for Travelan IND Application
23 déc. 2022 06h00 HE
|
Immuron Limited
Highlights: Immuron receives U.S. Food and Drug administration (FDA) approval for Travelan Investigational New Drug (IND) application IND to evaluate the efficacy of a single dose of Travelan to...